Shots:
- Minovia receives a $20M up front and is eligible to receive ~$420M per product in development, regulatory & commercial milestone for mitochondrial cell therapies caused by mitochondrial dysfunction
- The collaboration is to accelerate the allogeneic mitochondrial cell therapy programs & extend Astellas’ capabilities in mitochondrial biology. The collaboration follows the recent acquisition of Mitobridge and Nanna
- The goal is to treat mitochondrial dysfunction through the transfer of healthy mitochondria to restore the tissues. Currently, Minovia is conducting research, development, and clinical studies with MAT in mitochondrial diseases
Click here to to read full press release/ article | Ref: Astellas | Image: Behance
The post Astellas Signs a License Agreement with Minovia for Novel Mitochondrial Cell Therapy Programs first appeared on PharmaShots.